Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBP) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Regen BioPharma (RGBP) over the last 13 years, with Q4 2025 value amounting to $132964.0.

  • Regen BioPharma's Cash from Financing Activities rose 10207.6% to $132964.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $519595.0, marking a year-over-year decrease of 218.78%. This contributed to the annual value of $452430.0 for FY2025, which is 2832.39% down from last year.
  • As of Q4 2025, Regen BioPharma's Cash from Financing Activities stood at $132964.0, which was up 10207.6% from $227799.0 recorded in Q3 2025.
  • In the past 5 years, Regen BioPharma's Cash from Financing Activities ranged from a high of $1.4 million in Q3 2021 and a low of -$94535.0 during Q4 2021
  • Over the past 5 years, Regen BioPharma's median Cash from Financing Activities value was $132964.0 (recorded in 2025), while the average stood at $181961.5.
  • As far as peak fluctuations go, Regen BioPharma's Cash from Financing Activities tumbled by 9996.46% in 2022, and later soared by 2870761.52% in 2023.
  • Regen BioPharma's Cash from Financing Activities (Quarter) stood at -$94535.0 in 2021, then soared by 100.53% to $499.0 in 2022, then soared by 33125.85% to $165797.0 in 2023, then tumbled by 60.31% to $65799.0 in 2024, then surged by 102.08% to $132964.0 in 2025.
  • Its last three reported values are $132964.0 in Q4 2025, $227799.0 for Q3 2025, and $55976.0 during Q2 2025.